Neisseria meningitidis igtb los as adjuvant

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/39 (2006.01) A61K 39/095 (2006.01) A61P 31/00 (2006.01) C07H 3/06 (2006.01)

Patent

CA 2566409

The present invention relates to Neisserial Lipo-Oligo-Saccharides (LOS) that comprise a tri-saccharide outer core that shows increased binding to the DC- SIGN receptor on dendritic cells, as a result of which the Neisserial LOS~s of the invention have increased immunostimulatory activity. The tri-saccharide outer core of the Neiserial LOS~s combined with a Lipid A moiety with reduced toxicity is useful as an adjuvant in vaccine preparations.

L'invention concerne des lipo-oligosaccharides (LOS) de Neisserial comprenant une partie centrale extérieure assurant une liaison améliorée au récepteur DC-SIGN sur des cellules dendritiques, ce qui confère aux LOS de Neisserial une activité d'immunostimulation améliorée. La partie centrale extérieure du trisaccharide des LOS de Neisserial combinée à un fragment de lipide A à toxicité réduite est utile en tant qu'adjuvant dans des préparations de vaccins.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Neisseria meningitidis igtb los as adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neisseria meningitidis igtb los as adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neisseria meningitidis igtb los as adjuvant will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1709889

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.